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Abstract 
Background: 3,4-methylenedioxymethamphetamine (ecstasy) is understood to cause 
serotonin dysfunction and deficits in executive functioning. When investigating executive 
function, functional neuroimaging allows the physiological changes underlying these deficits 
to be investigated. The present study investigated behavioural and brain indices of inhibition 
in ecstasy-polydrug users. Methods: Twenty ecstasy-polydrug users and 20 drug-naïve 
participants completed an inhibitory control task (Random Letter Generation- RLG) while 
prefrontal haemodynamic response was assessed using functional Near Infrared Spectroscopy 
(fNIRS). Results: There were no group differences on background measures including sleep 
quality and mood state. There were also no behavioural differences between the two groups. 
However, ecstasy-polydrug users displayed significant increases in oxy-Hb from baseline 
compared to controls at several voxels relating to areas of the inferior right medial prefrontal 
cortex, as well the right and left dorsolateral prefrontal cortex. Regression analysis revealed 
that recency of ecstasy use was a significant predictor of oxy-Hb increase at two voxels over 
the right hemisphere after controlling for alcohol and cannabis use indices. Conclusion: 
Ecstasy-polydrug users show increased neuronal activation in the PFC compared to non-
users. This is taken to be compensatory activation/recruitment of additional resources to 
attain similar performance levels on the task, which may be reversible with prolonged 
abstinence.  
FUNDING:  
This research received no specific grant from any funding agency in the public, commercial, 
or not-for-profit sectors. 
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Introduction 
Ecstasy (MDMA/3,4-methylenedioxymethamphetamine) is a popular recreational 
drug which increases the release of serotonin (5HT- as well as other monoamine 
neurotransmitters dopamine and norepinephrine - McDowell & Kleber, 1994). Repeated 
administration of the drug may result in changes to serotonin axons. In addition, short-term 
down regulation of serotonin receptors may result from regular use in humans, similar to that 
proposed in animal models (Reneman et al., 2002). Indeed, it has been observed that doses 
comparable to those used recreationally in humans can produce long lasting decreases in 5-
HT content in animals (Green et al., 1995), reflecting neurodegeneration of 5-HT terminals. 
In humans, evidence from SPECT repeatedly suggests serotonin transporter (SERT) binding 
ratios are altered following repeated MDMA administration (Reneman, Booij et al., 2000; 
Reneman, Habraken et al., 2000).  More recently, PET studies have reported 5-HT2A receptor 
upregulation after chronic MDMA use over broad areas of the cerebral cortex, including: 
occipital parietal, frontal and frontoparietal regions (Di Iorio et al., 2012) and the dorsolateral 
prefrontal cortex (DLPFC) and parietal cortex (Urban et al., 2012), which is thought to be 
due to a loss or reduction in presynaptic signalling. Furthermore, McCann et al. (2008), Kish 
et al. (2010) and Erritzoe et al. (2011) found reduced SERT binding in abstinent users after 
recreational use, which is interpreted as compensatory down-regulation. A complicating 
factor emerges in research in recreational ecstasy users as the majority of individuals who 
report recreational use of ecstasy use a range of other drugs in addition to ecstasy (Fox et al., 
2001; Parrott et al., 2008; Roberts et al., 2013, 2014; Wetherell & Montgomery 2014); 
however, in most cases, they report that ecstasy is their “drug of choice”. Thus throughout the 
present paper, we refer to our sample as “ecstasy-polydrug users”.    
Working memory and executive functioning in humans is understood to rely on 
neuronal areas that are localised to the (dorsolateral) prefrontal cortex (Curtis & D’Esposito, 
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2003). These regions are densely populated with 5-HT receptors (Pazos et al., 1997). As such 
it could be expected that changes to 5-HT axons due to MDMA related serotonergic 
dysfunction, may result in cognitive deficits that are specific to the functions that these areas 
coordinate (Montgomery & Fisk, 2008; Reneman et al., 2006). Inhibitory control involves the 
suppression of prepotent, or dominant responses when they are not necessary. Behavioural 
research suggests that this executive function is relatively robust to ecstasy-related decline. 
Halpern et al. (2004) found ecstasy-related deficits on the Stroop task in a relatively pure 
ecstasy using sample, however this was not replicated in a follow up study (Halpern et al., 
2011). Moreover, using this task other studies have observed ecstasy users to be unimpaired 
in inhibition (Back-Madruga et al., 2003; Gouzoulis-Mayfrank et al., 2000). Using the 
Random Letter Generation (RLG) task, Wareing et al. (2000) observed performance deficits 
in ecstasy users compared to non-users, though these findings were not replicated by Fisk et 
al. (2004), using a larger sample and better matched controls for concomitant use of other 
drugs. Using Inhibition of Return as a measure of inhibitory control, Reay et al. (2006) found 
that ecstasy users performed comparably with controls, and this remained non-significant 
after controlling for concomitant drug use. Nevertheless it has been suggested that serotonin 
dysfunction and impairment of other executive functions may lead to poor inhibitory control 
(Morgan et al., 2006).  
While response inhibition appears to be preserved in ecstasy users, it remains a 
possibility that relatively subtle neuronal functioning alterations following chronic ecstasy 
use may not be detectable in performance measures, particularly if users are able to 
compensate for performance difficulties with reallocation of other cognitive resources. 
Burgess et al. (2011) observed differences in ecstasy users’ Event Related Potentials (ERPs) 
in a late positive component over left parietal scalp sites in a recall task that had yielded no 
significant performance deficits. The amelioration of this late positivity in ecstasy users is 
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described as a durable abnormality in processing that would not have been detected by 
behavioural measures alone. fMRI studies (e.g. Daumann, Fimm et al., 2003) have reported 
increased cortical activity in ecstasy users to compensate for behavioural differences. 
Furthermore Moeller et al. (2004) report increases in blood volume in ecstasy users relative 
to controls in several brain regions including the medial frontal gyrus and the thalamus, 
during a delayed memory task. These fMRI studies show increases in cortical activity and 
blood volume that potentially reflect compensatory mechanisms in ecstasy users. In effect, 
ecstasy users are working harder to achieve the same result behaviourally. 
Roberts and Garavan (2010) applied neuroimaging methodology to the investigation 
of response inhibition in ecstasy users. There were no observed ecstasy related performance 
deficits in on a Go/NoGo task, however fMRI data revealed that users showed increased 
frontal and parietal BOLD activation during successful inhibitions and hyperactivity of 
temporal, frontal and cingulate regions during commission errors. Similarly, in an ERP study 
investigating response inhibition with a Go/NoGo task, Roberts et al. (2013) observed 
atypical early processing in ecstasy users relative to controls that is suggestive of 
compensatory mechanisms to attenuate behavioural differences.  
Functional Near-Infrared Spectroscopy (fNIRS) is an optical neuroimaging technique 
that can be used to assess haemodynamic response in the PFC to cognitive demand (Ayaz, 
Shewokis et al., 2012). This technique uses near-infrared light at two wavelengths to attain 
estimates of oxygenated (oxy) and deoxygenated haemoglobin (deoxy-Hb) in the PFC. 
Typically fNIRS devices have a penetration depth of between 2 and 3 millimetres (Firbank et 
al., 1998), as such structures in the PFC can be accessed using this technology. This makes 
fNIRS an appropriate imaging tool for investigating executive functioning. Neuronal activity 
and haemodynamic response are tightly coupled, therefore increases in neuronal activity are 
understood to be indexed by an increase in oxy-Hb (Leff et al., 2011). Moreover, the 
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distribution of the activation response is regionally specific i.e. the source of the activity is 
the cortical region underlying the area where the response was observed (Leff et al., 2011). In 
general, the increase in Oxy-Hb from baseline can be conceptualised in terms of an increase 
in blood flow – the increase in glucose and oxygen utilisation results in an increase in the 
transport of both of these substances to an area of the brain and a subsequent surplus of 
oxygenation (Bunce et al., 2006; Fox et al., 1998). The increase in deoxy-Hb can be 
conceptualised in terms of oxygen utilisation – as oxygen is withdrawn from the oxygenated 
haemoglobin to be used in the task at hand, there is a resultant increase in deoxy-Hb (Obrig & 
Villringer, 2003).   
The current study assesses prefrontal haemodynamic response during cognitive 
inhibition in ecstasy-polydrug users and non-user controls. Task performance and 
haemodynamic changes from baseline were measured on each level of the task. Random 
Letter Generation (RLG) was used to assess inhibitory control. The task requires inhibitory 
control to avoid repeating letter sequences, producing alphabetical sequences and to generate 
random sequences. It is the suppression of habitual number or letter sequences that make 
RLG a task of cognitive inhibition (Friedman & Miyake, 2004). It was hypothesised that 
ecstasy-polydrug users would find the task more demanding, which would be indexed by an 
increase in oxy-Hb and deoxy-Hb over areas of the PFC relative to controls, and that this 
would increase as a function of task difficulty. In line with much of the behavioural literature, 
it was hypothesised that task performance differences between the two groups would be 
negligible. 
 
Method 
Design: 
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A quasi-experimental design was used with groups recruited from the North-West of 
England. Performance on the RLG task was analysed using MANOVA with group as a 
between groups factor (2 levels – ecstasy-polydrug user, nonuser), and scores at each rate (3 
levels, 4, 2 and 1-second rate), as the dependent variable. For fNIRS analysis group with 2 
levels (ecstasy-polydrug user, nonuser) was the between groups variable and mean 
oxygenated and deoxygenated haemoglobin change at each voxel (1-16) for each level of 
difficulty was the dependent variable. Stepwise Linear regression analyses were used to 
assess the relationship between oxygenation change and indices of ecstasy, cannabis and 
alcohol use.    
Participants: 
A total of twenty ecstasy-polydrug users (mean age = 21.85±2.76; 13 male) and 20 non-user 
controls (mean age = 20.89±2.05; 7 male) were recruited via email to university students in 
Liverpool. For inclusion in the study, participants must be aged 18-29 years and report no 
current or past-year diagnosis of a psychological disorder (e.g. GAD, Major Depressive 
Disorder). Ecstasy-polydrug using participants must report at least 5 lifetime occasions of use 
(actual minimum = 11); indices of ecstasy and other drug use are displayed in Table 2. To be 
considered a nonuser, participants must have never used ecstasy/MDMA; the nonuser group 
primarily consisted of drug naïve participants. All participants were required to abstain from 
drug use for a minimum of 7 days prior to testing (confirmed via self-report).  
<<Insert Table 2 about Here>> 
Materials:  
A number of questionnaires were issued to participants upon entering the lab including:  
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Background Drug Use Questionnaire (Montgomery et al., 2005), from which drug use 
indices (frequency of use, last 30 days use, first and last use, patterns of use), as well as 
lifestyle and socio-demographic variables, are derived. Estimates of total lifetime use, as well 
as totals for last 30 days use and weekly use estimates, of each drug were calculated using the 
method employed by Montgomery et al. (2005). 
Measures of Sleep Quality: 
It has been suggested that differences in lifestyle variables such as sleep and the subacute 
effects of drugs on mood state may mediate cognitive deficits in ecstasy users (Cole et al., 
2002). Thus to assess any potential relationship between sleep and cognition, participants 
were given various alertness and sleep quality questionnaires including: The Epworth 
Sleepiness Scale (ESS; Johns, 1991) which explores the likelihood of dozing or falling asleep 
in various situations, and as such is a measure daytime sleepiness (high score = increased 
subjective sleepiness); The Morningness-Eveningness Questionnaire (MEQ; Termann et al., 
2001) measuring subjective morningness-eveningness traits due to differences in human 
circadian rhythms (high MEQ score indicates morning type, low score indicates evening type 
person); and the Karolinska Sleepiness Scale (KSS; Akerstedt & Gillberg, 1990)  measuring 
subjective sleepiness at the current moment in time, as such, this was completed pre and post 
task. 
Mood State: 
To control for any potential differences in mood state, state anxiety, arousal and hedonic tone 
were assessed using the scale devised by Fisk and Warr (1996). Ratings of current mood at 
the time of testing were made using a Likert scale (1 = not at all, 5 = extremely). A high score 
on each scale relates to increased hedonic tone/anxiety/arousal. 
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 Raven’s Progressive Matrices (SPM; Raven, Raven, & Court, 1998) 
Fluid intelligence was assessed using Raven’s SPM. Participants are required to select an 
appropriate response from a choice of 6/8 options to complete a symbolic sequence. Five sets 
of 12 problems are presented (60 in total). Each block of 12 problems starts with an 
intuitively simple problem and the difficulty increases as the task progresses. 
Random Letter Generation (Baddeley, 1966)   
Participants were presented with a bar on the screen that alternated between two positions at a 
set pace, cueing participants to generate a letter. Participants had to produce 100 letters in 
each block of the task, with a 1-minute rest between each block. There were three blocks and 
each block represented a different production rate (one letter every 4, 2, and 1-seconds), thus 
total time to complete the task was around 15-minutes. Participants were instructed to avoid 
alphabetical sequences, repetition of sequences of letters and to produce each letter with the 
same overall frequency. Presentation of blocks was randomised and participants’ responses 
were recorded onto a cassette deck with a built in microphone. Four scores were generated – 
the number of alphabetically ordered pairs, the number of repeat sequences, “redundancy” 
(the extent to which all letters are produced equally with 0% being truly random) and the 
number of letters produced. A high score on the first three indicates poor performance 
whereas the opposite is true in the fourth case. All scores were standardised and a single 
score for each random generation measure was obtained by calculating the mean standardised 
scores for the three production rates (as per Montgomery et al., 2005). 
Equipment 
Task-related haemodynamic response was monitored using a continuous-wave fNIRS system 
(developed by Drexel University, Philadelphia, PA) supplied by Biopac systems (Goleta, CA, 
USA). The temporal resolution of the fNIRS sensor is 2Hz (500ms per scan), with a source-
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detector separation of 2.5cm allowing 1.25cm cortical penetration depth (Ayaz, Shewokis et 
al., 2012). Data acquisition and visualisation were performed using an fNIR100 control box 
and COBI studio (Drexel University) during data collection (as per Ayaz et al., 2011; Ayaz, 
Shewokis et al., 2012). Figure 1 displays the anatomical locations of the sensors on the PFC.  
<<Insert Figure 1 here>> 
Procedure 
Participants attended a single lab session lasting approximately 2 hours. Sessions started at 
9am, 11am, 1pm and 3pm, with equal numbers of each group tested at each time. Participants 
received an information sheet upon arrival at the lab, giving full details of the study. After 
participants had read the information sheet, written consent was obtained. Questionnaires 
were administered in the following order: background drug use questionnaire, MEQ, ESS, 
pre-test KSS, UMACL and Raven’s SPM. Upon completion of the questionnaires, the fNIRS 
sensor was fitted to the participant’s forehead. fNIRS signals were displayed on a desktop 
computer running COBI studio (Drexel University) in an adjacent room to the testing room. 
After stabilisation of the fNIRS signals, a baseline of inactivity was recorded. During this 
baseline recording period participants watched a video of planet earth accompanied by 
soothing music. Following the baseline recording participants were instructed to complete the 
RLG task. Once the RLG task was complete participants were given the post task KSS. 
Participants were fully debriefed after the testing procedure and were paid £20 in store 
vouchers. The study was approved by Liverpool John Moores University Research Ethics 
Committee, and was administered in accordance with the ethical guidelines of the British 
Psychological Society. 
Analysis 
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fNIRS raw data from COBI studio was pre-processed using fNIRSOFT (Biopac systems; 
Goleta, CA, USA). All 16 voxels (oxy and deoxy-Hb) were visually inspected for light 
saturation and any saturated voxels were discarded. Noise due to respiration was removed 
using a high-pass filter (0.1Hz cut off) and high frequency noise was removed using a linear 
phase filter (order of 20) (Ayaz et al., 2011; Ayaz, Shewokis et al., 2012). Oxy and deoxy-Hb 
changes from baseline were calculated for each voxel, at each rate of the task, using the 
modified Beer-Lambert law logarithm in fNIRSOFT (Ayaz et al., 2010). Between group 
differences in oxy and deoxy-Hb change from baseline at each production rate of the task (4, 
2 and 1s) were assessed using a series of ANOVAs. 
Standardised scores for alphabetically ordered pairs, repeat sequences and redundancy 
were added together and the standardised score for the number of letters produced was 
subtracted from this total, this new total was then divided by four, to give a single 
standardised performance score for each rate (1s, 2s and 4s) for each participant. MANOVA 
was used to analyse the 3 RLG scores.   
Results 
RPM score, ESS, KSS and MEQ scores and scores of anxiety, hedonic tone and arousal are 
shown in Table 1, along with socio-demographic information. Indices of other drug and 
alcohol use are displayed in Table 2.  
<<Insert Table 1 Here>> 
There were no significant between groups differences in age t(36) = 1.21, p>.05, total scores 
on the ESS t(37) = -0.28, p>.05, MEQ t(30) = -.1.37, p>.05, Raven’s SPM t(38) = -0.41, 
p>.05, pre-test KSS t(38) = -0.88, p>.05, post-test KSS t(26) = 1.59, p>.05, or levels of 
arousal t(38) = -0.28, p>.05, hedonic tone t(38) = 0.41, p>.05 and anxiety t(38) = -0.07, 
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p>.05. Ecstasy-polydrug users did, however, report drinking significantly more units of 
alcohol per week than non-users t(38) = 2.71, p<.01. Furthermore, as can be observed in 
Table 2, the ecstasy-polydrug user group does report concomitant use of other drugs.  
Behavioural Data Analysis: 
Scores for each component measure on RLG (Redundancy, repeat sequences, alphabetical 
sequences and number of letters produced) at each rate can be observed in Table 3. 
MANOVA revealed no significant main effect of group, F(3,36) = 0.85, p>.05 for Pillai’s 
trace. Univariate ANOVA revealed no significant between group differences on performance 
at each individual rate; 1s F(1,38) = 0.01, p>.05, 2s F(1,38) = 1.75, p>.05 or 4s F(1,38) = 
0.93, p>.05. 
<<Insert Table 3 Here>> 
fNIRS Analysis 
Figure 2 displays averaged oxy and deoxy-Hb changes from baseline over each epoch at each 
rate of the task. ANOVA on oxy-Hb change from baseline on the first level of difficulty of 
the task (4s rate) revealed that ecstasy-polydrug users showed increased oxy-Hb compared to 
controls at V10 F(1,30) = 2.96, p<.05 and this difference was approaching significance at V1 
F(1,33) = 2.00, p=.08. There were no significant differences at any of the other voxels 
measured (p>.05). 
<<Insert Figure 2 Here>> 
There were also significant differences in the amount of deoxy-Hb change from baseline at 
V3 F(1,35) = 5.42, p<.05, V4 F(1,16) = 3.90, p<.05, V5 F(1,36) = 2.92, p<.05, V13 F(1,36) 
= 6.11, p<.01, V14 F(1,34) = 3.11, p<.05, V15 F(1,34) = 4.93, p<.05 and V16 F(1,35) = 
5.37, p<.05, whereby ecstasy-polydrug users showed greater deoxygenation change than 
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controls. This difference was also approaching significance at V2 F(1,32) = 2.64, p=.06, V10 
F(1,30) = 2.44, p=.06, V11 F(1,20) = 2.19, p=.08 and V12 F(1,31) = 2.37, p=.07. No other 
differences were observed for the other voxels measured (p>.05 in each case). 
At the medium level of difficulty in this task (2s rate) ANOVA revealed between 
group differences in oxy-Hb at V4 F(1,16) = 3.47, p<.05, V10 F(1,30) = 3.52, p<.05, and 
V12 F(1,31) = 4.45, p<.05 whereby ecstasy-polydrug users showed greater oxy-Hb increase 
from baseline than controls. This difference was approaching significance at V11 F(1,20) = 
2.65, p=.06 and V14 F(1,34) = 2.75, p=.06. There were no differences at any other voxels 
(p>.05). 
ANOVA on deoxy-Hb changes at the 2-s rate revealed that ecstasy-polydrug users 
had significantly greater deoxy-Hb increase than controls at V2 F(1,32) = 4.33, p<.05, V4 
F(1,16) = 4.47, p<.05, V11 F(1,20) = 2.84, p<.05, V13 F(1,36) = 5.12, p<.05, V14 F(1,34) = 
3.67, p<.05 and V15 F(1,34) = 3.48, p<.05. This difference was also approaching 
significance at V3 F(1,35) = 2.56, p=.06, V5 F(1,36) = 2.27, p=.07, V10 F(1,30) = 2.10, 
p=.08 and V12 F(1,31) = 1.83, p=.09. No other significant differences were observed (p>.05 
in each case). 
For the most difficult level of the task (1s rate) ANOVA revealed that ecstasy-
polydrug users displayed significantly increased oxy-Hb from baseline relative to controls at 
V12 F(1,31) = 3.08, p<.05 and V14 F(1,34) = 3.42, p<.05. This difference was also 
approaching significance at V13 F(1,36) = 1.83, p=.09. There were no other significant 
differences at any of the voxels measured (p>.05 in each case). 
ANOVA on the deoxy-Hb data in this block revealed that ecstasy-polydrug users 
displayed significantly greater deoxy-Hb than controls at V2 F(1,32) = 4.24, p<.05, V3 
F(1,35) = 3.07, p<.05, V4 F(1,16) = 7.20, p<.01, V5 F(1,36) = 3.18, p<.05, V11 F(1,20) = 
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3.05, p<.05, V13 F(1,36) = 7.28, p<.01, V14 F(1,34) = 5.55, p<.01 and V15 F(1,34) = 6.14, 
p<.01. This difference was also approaching significance at V12 F(1,31) = 2.50, p=.06 and 
V16 F(1,35) = 2.59, p=.06. There were no significant differences at the other voxels 
measured (p>.05 in each case). 
In summary, at the slowest rate (4second rate), that is understood to be the easiest 
level of the task, increases in oxy-Hb were observed in V10 relating to the right medial PFC 
in ecstasy-polydrug users. As difficulty increased, a more pronounced difference between 
ecstasy-polydrug users and controls was observed. During the second block of the task (2 
second rate) ecstasy-polydrug users displayed significant increases in oxy-Hb relative to 
controls at voxels 4, 10 and 12. This indicates a bilateral induction of oxy-Hb increase. At the 
most difficult level of the task (1 second rate), ecstasy-polydrug users displayed significant 
increases in oxy-Hb in voxels relating to inferior parts of the right medial PFC and right 
DLPFC (V12 and V14). Although, this is a less pronounced difference than in block two, 
there were complimentary increases in deoxy-Hb that suggest more pronounced differences 
between users and non-users as a function of difficulty. A total of eight voxels, showed 
significant between group differences in deoxy-Hb at the one second rate, compared to six 
voxels at the two second rate and seven voxels at the four second rate. In each case, increases 
in deoxy-Hb, were observed over the breadth of the prefrontal cortex, suggesting that 
induction of haemoglobin in ecstasy-polydrug users during inhibition is bilateral.    
<<Insert Table 4 about here>> 
In animal models, cumulative dosing is an important factor in neurotoxic damage (See 
Gouzoulis-Mayfrank and Daumann (2009) for review). Consequently, we tested the 
relationship between cumulative lifetime dose and fNIRS parameters. Significant correlations 
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are displayed in Table 4, and indicate that increased use is associated with greater 
oxygenation change.  
As there was a high level of cannabis use amongst the ecstasy-polydrug user group, 
and all participants reporting drinking alcohol frequently, multiple regression analyses were 
conducted on all voxels showing significant between group differences in oxy-Hb and deoxy-
Hb. This was conducted to observe whether ecstasy use indices predicted oxy-Hb and deoxy-
Hb increase after controlling for cannabis and alcohol use. Values of oxy-Hb or deoxy-Hb 
(µmolar) were entered as dependent variables. In step one indices of alcohol and cannabis use 
were entered as predictors (frequency of use, total lifetime dose, amount smoked in the last 
30 days), in step two the same indices of ecstasy use were entered as predictors. For brevity, 
only regressions yielding notable results are reported here. 
The regression model using deoxy-Hb at V14 during the 4s rate as the dependent 
variable, accounted for a significant 57.6% (R² = 0.58, R² adjusted = 0.47, F(7,28) = 5.43, 
p<0.01) of the variance in deoxy-Hb. Alcohol and cannabis use indices (step 1) did not 
predict a significant amount of variance in V14 deoxygenation change (R² = 0.06, R² adjusted 
= -0.06, F(4,31)=0.48, p>0.05). None of the individual cannabis use indices were significant 
predictors; frequency of use (β=-0.08, p>0.05), total lifetime dose (β=0.31, p>0.05) and 
amount smoked in the last 30 days (β=-0.41, p>0.05), however alcohol use was a significant 
predictor (β=-0.46, p<0.01) with increased use being associated with decreased deoxy-Hb. 
The ecstasy use indices (step 2) did, however, predict a significant amount of variance in V14 
deoxy-Hb, after controlling for cannabis use indices (R² change=0.52, F(3,28)=11.38, p<.01). 
Individual indices; last 30 day use (β=1.00, p<0.05) predicted V14 deoxy-Hb level at the 4s 
rate and frequency of use approached significance as a predictor (β=-0.32, p=0.06), with 
increased last 30 day use being associated with increased deoxy-Hb and increased frequency 
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being associated with decreased deoxy-Hb. Lifetime dose (β=0.05, p>0.05) was not a 
significant predictor. 
The regression model using deoxy-Hb at V14 during the 2s rate as the dependent 
variable, accounted for a non-significant 53.9% (R² = 0.54, R² adjusted = 0.22, F(7,10) = 
1.67, p>0.05) of the variance in deoxy-Hb. Alcohol and cannabis use indices (step 1) did not 
predict a significant amount of variance in V14 deoxy-Hb (R² = 0.27, R² adjusted = 0.04, 
F(4,13) = 1.17, p>0.05). Alcohol use was not a significant predictor, although this did 
approach significance (β=-0.57, p=0.06) with increased use being associated with decreased 
deoxy-Hb. None of the individual cannabis use indices were significant predictors; frequency 
of use (β=-0.16, p>0.05), total lifetime dose (β=-0.13, p>0.05) and amount smoked in the last 
30 days (β=-0.26, p>0.05). Ecstasy use indices (step 2) did not predict a significant amount of 
variance in V14 deoxy-Hb, after controlling for cannabis use indices (R² change=0.27, F-
change (3, 10)=1.98, p>.05). Individual indices; frequency of use (β=-0.34, p>0.05) and 
lifetime dose (β=0.00, p>0.05) did not predict V14 deoxy-Hb increase at the 2s rate. However 
last 30 day use (β=0.69, p<0.05) was a significant predictor with increased use being 
associated with increased deoxy-Hb. 
The regression model using oxy-Hb at V12 during the 1s rate as the dependent 
variable, accounted for a close to significant 39.2% (R² = 0.39, R² adjusted = 0.22, F(7,25) = 
2.31, p=0.06) of the variance in oxy-Hb. Alcohol and cannabis use indices (step 1) did not 
predict a significant amount of variance in V12 oxy-Hb (R² = 0.24, R² adjusted = 0.13, 
F(4,28) = 2.19, p>0.05). Alcohol use was not a significant predictor (β=-0.07, p>0.05) neither 
were any of the individual cannabis use indices; frequency of use (β=0.08, p>0.05), total 
lifetime dose (β=-0.16, p>0.05) and amount smoked in the last 30 days (β=0.39, p>0.05). 
Ecstasy use indices (step 2) did not predict a significant amount of variance in V12 oxy-Hb, 
after controlling for cannabis use indices (R² change=0.15, F-change (3, 25)=2.12, p>.05). 
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Individual indices; frequency of use (β=-0.25, p>0.05) and lifetime dose (β=0.03, p>0.05) did 
not predict V12 oxy-Hb increase at the 1s rate. However last 30 day use (β=0.55, p<0.05) 
was a significant predictor with increased use being associated with increased oxy-Hb. 
The regression model using oxy-Hb level at V14 during the 1s rate as the dependent 
variable, accounted for a non-significant 34% (R² = 0.34, R² adjusted = 0.18, F(7, 28) = 2.06, 
p>0.05) of the variance in oxy-Hb. Alcohol and cannabis use indices (step 1) did not predict a 
significant amount of variance in V14 oxy-Hb (R² = 0.19, R² adjusted = 0.09, F(4,31)=1.81, 
p>0.05). None of the individual alcohol or cannabis use indices were significant predictors; 
alcohol use (β=-0.05, p>0.05), frequency of use (β=0.11, p>0.05), total lifetime dose (β=0.17, 
p>0.05) and amount smoked in the last 30 days (β=0.20, p>0.05). Ecstasy use indices (step 2) 
did not predict a significant amount of variance in V14 oxy-Hb, after controlling for cannabis 
use indices (R² change=0.15, F-change (3, 28)=2.13, p>.05). Individual indices; frequency of 
use (β=-0.26, p>0.05) and lifetime dose (β=-0.19, p>0.05) did not predict V14 oxy-Hb level 
at the 1s rate. However, last 30 day use (β=0.51, p<0.05) was a significant predictor, with 
increased use being associated with increased oxy-Hb change. 
The regression model using deoxy-Hb at V14 during the 1
st
 rate as the dependent 
variable, accounted for a significant 37.9% (R² = 0.38, R² adjusted = 0.22, F(7, 28) = 2.44, 
p<0.05) of the variance in deoxy-Hb. Alcohol and cannabis use indices (step 1) did not 
predict a significant amount of variance in V14 deoxy-Hb (R² = 0.03, R² adjusted = -0.09, 
F(4,31) = 0.27, p>0.05). None of the individual alcohol or cannabis use indices were 
significant predictors; alcohol use (β=-0.33, p>0.05), frequency of use (β=-0.07, p>0.05), 
total lifetime dose (β=0.43, p>0.05) and amount smoked in the last 30 days (β=-0.27, 
p>0.05). However, ecstasy use indices (step 2) did predict a significant amount of variance in 
V14 deoxy-Hb, after controlling for cannabis use indices (R² change=0.35, F-change (3, 
28)=5.19, p<.01). Individual indices; frequency of use (β=-0.30, p>0.05) and lifetime dose 
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(β=-0.08, p>0.05) did not predict V14 deoxy-Hb level at the 1s rate. However, last 30 day use 
(β=0.82, p<0.01) was a significant predictor, with increased use being associated with 
increased deoxy-Hb level. 
In summary, the majority of the regression analyses, on voxels showing significant 
between group differences, to observe whether ecstasy use predicted oxy and deoxy-Hb 
increases after controlling for cannabis use indices, were non-significant. However ecstasy 
use indices predicted a significant amount of the variance in deoxy-Hb at voxel 14, in the 
four second rate and two second rate of the task.  Specifically last 30 days use was a 
significant predictor, with increased use being associated with increased deoxy-Hb. 
Frequency of use also approached significance as a predictor at V14 at the four second rate, 
whereby increased frequency of use was associated with reduced deoxy-Hb. Last 30 days use 
was also a significant predictor of oxy-Hb increase at V12 and V14 in the 1 second rate 
block, with increased use being associated with increased oxygenation. Last 30 days use also 
predicted deoxy-Hb increase at V14 at the one second rate. The results from regression 
analyses suggest that recency of ecstasy use may play an important role in the observed 
cognitive function alterations during inhibition. 
Comparing the roles of ecstasy vs. cocaine use:  
In the ecstasy-polydrug group, 11 participants reported regular use of cocaine. To attempt to 
investigate the relative roles of ecstasy and cocaine in this group, we have re-ran the analyses 
with various IVs instead of the IV “ecstasy-polydrug use”. In the first analysis, we recoded 
the data so that we had cocaine user versus cocaine naive participants, and we disregarded the 
factor of ecstasy or any other drug use. Using cocaine user/nonuser as the IV, the main effect 
of cocaine use on RLG performance was non-significant: F(3,36) = 1.76, p>.05, as were all 
of the univariate analyses (p>.05 in all cases). For the fNIRS data there were no significant 
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differences on any of the oxy or deoxy changes from baseline, for any voxel, at any of the 3 
rates. Differences in change at V14 at the 1-second rate approached significance F(1,34) = 
3.62, p = 0.07. This suggests that the results observed in the present paper are not due the use 
of cocaine alone.  
Furthermore, we then excluded all cocaine users from the sample and compared the 
remaining ecstasy users with the non-ecstasy users. Consequently we had a sample of ecstasy 
users who had not used cocaine and a sample of non-users. The main effect of ecstasy use on 
RLG performance was non-significant, as it was in the original analysis reported in this paper 
F(3,25) = 0.11, p>.05. All of the univariate effects on RLG were also non-significant.  
For the fNIRS data, at the 1-second rate there was a significant difference in oxy-Hb 
change at V10 F(1,22) = 4.03, p<.05. For the 1-s deoxy data, there were significant 
differences at V2 F(1,21) = 5.65, p<.05; V4 F(1,21) = 7.68, p<.05; V5 F(1,25) = 3.90), p<.05; 
V13 F(1,25) = 7.26, p<.01; V14 F(1,23) = 5.08, p<.05 and V15 F(1,24) = 5.81, p<.05. There 
were also differences approaching significance at 7 other voxels in total for the 1-s rate. For 
the 2-s rate, there were significant differences in oxy-Hb change at V4 F(1,21) = 4.70, p<.05 
and V10 F(1,21) = 6.73, p<.05. There were also significant differences in deoxy change at 
V13 F(1,25) = 4.70, p<.05 and V15 F(1,25) = 4.27, p<.05. In addition, there were 4 
approaching significance at the 2-s rate. For the 4-s rate there were no significant differences 
in oxy-Hb change. There were however a number of significant differences in deoxy-Hb 
change at V2 F(1,21) = 4.15, p<.05; V3 F(1,24) = 4.84, p<.05; V4 F(1,21) = 4.62, p<.05; V5 
F(1,25) = 4.40, p<.05; V6 F(1,24) = 4.08, p<.05; V13 F(1.25) = 6.46, p<.05 and V15 F(1,24) 
= 5.58, p<.05. In addition, there were 4 voxels approaching significance at the 4-s rate.  
When this second analysis is compared to the original results including all 
participants, for the 4-second rate, the changes in oxy-Hb at V10 have been reduced to 
approaching significance, as have the differences in deoxy-Hb at V14 and 16. However all 
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other voxel changes remained significant after excluding cocaine users, in addition to extra 
voxels which were not significant in the first analysis (V2 and V6 deoxy-Hb). For the 2-
second rate, changes in oxy-Hb change at V4 and 10 remained significant, though changes at 
V12 were now approaching significance. Changes in V13 and V15 deoxy-Hb also remained 
significant. For the 1-s rate, changes in oxy-Hb at V12 and V14 were now approaching 
significance, though changes at V10 were significant. Changes in deoxy-Hb remained 
significant at V2, V4, V5, V13, V14 and V15. Changes at V3 and V11 now approached 
significance. Overall, exclusion of cocaine users does not reduce most of the significant 
effects to below statistical significance. In some cases, effects were reduced to below 
statistical significance; however, they still approached significance at p = 0.06 or p = 0.07, 
and we propose that this reduction in statistical significance is due to a reduction in sample 
size.  
 
Discussion 
This study investigated the effects of ecstasy/MDMA-polydrug on the haemodynamic 
response to inhibitory control. The ecstasy-polydrug users in this sample did not differ 
significantly from controls in fluid intelligence, sleep measures or levels of arousal, 
depression or anxiety. There were no significant differences in performance on the 
behavioural task.  However, as predicted ecstasy-polydrug users did display alterations to 
neuronal activation. Ecstasy-polydrug users displayed increases in oxy-Hb compared to 
controls that reflect increases in effortful cognition, furthermore increases in deoxy-Hb were 
observed in ecstasy-polydrug users relative to controls during the RLG task; taken together 
these findings suggest that ecstasy-polydrug users have both increased blood flow and 
increased oxygen utilisation relative to nonusers. Recency of ecstasy use was related to 
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indices of oxygenation change suggesting that there may be reversibility with prolonged 
abstinence.   
On the easier level of the task (generation rate of 4s), ecstasy-polydrug users showed 
significant increases in oxy-Hb at one voxel (V10) in the right medial PFC and one voxel that 
was approaching significance in the left DLPFC (V1). However deoxy-Hb was also increased 
in ecstasy-polydrug users relative to controls at several voxels relating the left DLPFC and 
the right DLPFC. When difficulty was increased (2 second rate) a stronger haemodynamic 
response was observed in the ecstasy-polydrug user group. Increased levels of oxy-Hb were 
observed in V4 relating to the left DLPFC, and V10 and V12 relating to the (inferior) right 
medial PFC compared to controls. A further two voxels (V1 and V14) also approached 
significance. Significantly more deoxy-Hb was observed in six voxels in ecstasy-polydrug 
users compared to controls, covering the spectrum of the PFC. This marked increase in 
different voxels suggests that neuronal activation is increasing as a function of difficulty. 
Again in the most difficult block of the task (generation rate of 1s) ecstasy-polydrug users 
display significant increases in oxy-Hb at two voxels V12 (located on the inferior part on the 
right medial PFC) and V14 (relating to the right DLPFC), with a third (V13) approaching 
significance. This was a less pronounced difference than at the two second rate, however 
there was an increase in the number of voxels showing increased deoxy-Hb (a total of 8 
voxels, primarily relating to the left DLPFC and right DLPFC, with a further two 
approaching significance). This shows a general increase in neuronal activity at this rate, if 
we consider that the total amount of haemoglobin to the prefrontal cortex appears increased. 
This supports the existing evidence that suggests ecstasy-polydrug users are more greatly 
affected when greater cognitive load is placed upon them (Montgomery et al., 2005; Wareing 
et al., 2000). Moreover, the changes in oxy and deoxy Hb are correlated with extent of 
ecstasy use. Total lifetime dose of ecstasy correlates positively with oxygenation change in a 
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range of voxels related to areas of the left and right DLPFC. This was most pronounced (both 
in terms of number of significant correlations and strength of correlations) at the 1-second 
rate, further supporting the effects of heavy use on more demanding tasks.  
The increase in neuronal activation observed in this inhibitory control task is bilateral 
and suggests that ecstasy-polydrug users find this task more difficult than non-users. Meta-
analysis of neuroimaging data during cognitive functions suggest a network of PFC regions 
are regularly active, including bilateral activation of the DLPFC, inferior frontal cortex and 
anterior cingulate cortex (Duncan & Owen, 2000). Interestingly, a review of lesion studies 
(Aron et al., 2004), suggested that although the network of PFC areas described above is 
necessary for inhibitory control, the right inferior frontal cortex is of particular importance in 
this function. This is consistent with the current results that observe consistently increased 
oxy-Hb in inferior voxels relating to the right of the PFC (V10 and V12) for ecstasy-polydrug 
users. Ayaz, Cakir et al. (2012) have previously highlighted the importance of measuring 
haemodynamic response to tasks in subjects that perform at a similar level, as there may be a 
dissociation between cognitive effort and performance output. It was argued that performance 
can be maintained at necessary levels with increased mental effort or strategic alterations. 
However increased mental workload is predictive of performance deterioration following 
increased demand or task changes. Oxy-Hb increase reflects increased cognitive effort. As 
such increased Oxy-Hb on tasks that yield similar performance outcomes may reflect 
recruitment or additional cognitive resources. The differential activation patterns as a 
function of task difficulty require more explanation. Previous studies by Rubia and co-
workers (Rubia et al., 2000, 2001) suggest that the right inferior PFC shows activation along 
with other prefrontal, parietal, temporal and subcortical regions during inhibitory 
performance in stop signal and go no-go tasks. Rubia et al. (2003) isolate the right inferior 
PFC as being crucial for successful inhibitory control, with other activated regions being 
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responsible for “uncontrolled non-inhibitory cognitive functions such as response selection, 
response competition, or low-frequency detection”. One potential explanation for the pattern 
of results in the present study could be that areas that are specific for inhibitory control (right 
inferior PFC) remain increased for ecstasy-polydrug users consistently (with this being 
greatest at the most difficult level of the task), whereas other areas that are generically 
involved in task performance, but not necessarily specific to inhibition show a drop off in 
activation under the more demanding conditions. The 1-second rate, the most difficult level, 
shows activation which suggests an inhibition specific cognitive deficit in ecstasy-polydrug 
users.   
There is now extensive evidence that ecstasy alters serotonin neurons, and that this is 
related to memory impairment, though there may be some degree of reversibility. McCann et 
al. (2008) found reduced SERT binding particularly in the DLPFC in abstinent users, which 
was related to memory deficits. Similarly Kish et al. (2010) observed changes to cortical but 
not subcortical serotonin neurons after recreational ecstasy use, and Erritzoe et al. (2011) 
observed reduced SERT binding in human users (See Parrott, 2013 for review). In line with 
previous research it seems logical that serotonin-rich areas in the PFC that are necessary for 
performing executive tasks would require additional resources, or would show increased 
activation as a function of increased demand. The current study provides further support for 
the argument that ecstasy-polydrug users are recruiting additional resources to perform at a 
similar level as controls on the task. This is in line with results from ERP data on inhibition 
(Roberts et al., 2013), which suggests ecstasy users display atypical processing, despite 
equivalent behavioural performance. Moreover, Roberts and Garavan (2010) observed that 
ecstasy users displayed increased frontal and temporal BOLD activation compared to controls 
during a Go/NoGo task, in an fMRI study. Furthermore, several other neuroimaging studies 
report prefrontal haemodynamic changes in ecstasy users (Jager et al., 2008; Moeller et al., 
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2004). Each of these fMRI studies (Jager et al., 2008; Moeller et al., 2004; Roberts & 
Garavan, 2010) report that ecstasy users achieve similar performance on tasks as controls, 
with increased neuronal activity as a compensatory mechanism. To further support this, 
Wetherell et al. (2012) found that despite equivalent performance in a multi-tasking stressor, 
ecstasy users had heightened psychological stress responses indicating that they found the 
task more demanding and stressful than nonusers.  These findings are in agreement with the 
current study and also reflect the sensitivity of neuroimaging techniques for the detection of 
subtle cognitive changes. 
Morgan et al. (2006) suggested that serotonin dysfunction and impairment of other 
executive functions may lead to poor inhibitory control. Taken together these results reflect 
evidence of ecstasy-polydrug-related changes in brain processes. The regression analyses on 
the present dataset showed that last 30 day use significantly predicted oxy-Hb increase in 
voxels 12 and 14 during the one second rate of the task, after controlling for cannabis use 
indices. This is indicative of recency of MDMA use having implications for inhibitory 
control. Indeed Hoshi et al. (2007) observed impaired inhibitory control in ecstasy users 
which they suggest is related to recency of use, given that current users were impaired, but 
former users were not. It is suggested that abstention may lead to recovery of this function, 
and future research should seek to clarify this further.   
Although there are strong, significant differences between ecstasy-polydrug users and 
controls in their haemodynamic response to the RLG task, interpretation of these results does 
require some caution. The ecstasy users in this sample are polydrug users, thus it cannot be 
ruled out that the effects observed are not a result of concomitant use of other drugs. 
Attempts were made to statistically control for cannabis (the most prominently co-used drug) 
use, and alcohol use with regression analyses. Recency of ecstasy use was the strongest 
predictor of Oxy-Hb increase, as this was a significant predictor at two voxels after 
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controlling for cannabis use indices, this suggests that ecstasy use is most likely to be 
responsible for differences observed in this study. Furthermore, due to the primarily drug 
naïve nature of the control group in this study, it cannot be ruled out that between group 
differences reflect pre-morbid differences that are associated with propensity for drug use. 
Other potentially confounding variables were also attempted to be controlled for such as fluid 
intelligence, sleep measures and levels of anxiety depression and arousal. There were no 
between group differences in any of these variables. There was also an uneven gender 
distribution between the groups, though not significantly so. As men and women may differ 
in their performance in such tasks, future research should seek to match groups on gender. 
Self-report of background dug use may also be criticised in terms of accuracy, especially 
given the implications of memory deficits that are associated with substance use. However 
this method is commonly used in this research area (Montgomery et al., 2005: Roberts et al., 
2014). In our recent work, very low levels of recent use were found in participants’ urine, and 
exclusion of participants with positive screens did not change the significant effects (Roberts 
et al., 2013). Scholey et al. (2011) found that objective analysis of hair samples in ecstasy 
users were consistent with self-reports, thus we believe that the use of self-report in the 
present study does not undermine the significant findings. The purity of the ecstasy tablets, as 
well as the cocaine purity and cannabis strength cannot be verified. However a report by 
Parrott (2004) suggested that ecstasy tablet purity was approaching 100% in nightclubs in the 
UK. If this is no longer the case and the purity of the tablets consumed by the current sample 
of participants is lower, then this would raise additional concern over the magnitude of the 
findings reported here (Montgomery et al., 2010). Finally, while Miyake and co-workers 
(Friedman & Miyake 2004; Miyake et al., 2000) argue that RLG is an inhibition task, Fisk 
and Sharp (2004), suggest that a component of RLG – the redundancy measure does require a 
component of semantic access. As ecstasy-related deficits in semantic access have been 
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observed previously (Montgomery et al., 2005), it remains a possibility that the results of the 
present study reflect not only increased effort for inhibitory control in ecstasy-polydrug users, 
but also semantic access.  
The present study provides evidence of neuronal functioning alterations in ecstasy 
polydrug users compared to controls during an inhibitory control task. Ecstasy-polydrug users 
displayed significant increases in oxy-Hb in voxels located over the left and right DLPFC, as 
well as the inferior right medial PFC compared to controls during random letter generation. 
This is likely to reflect recruitment of additional resources as a compensatory mechanism, 
given that performance output was of a similar level in both groups. The results indicate that 
overall ecstasy-polydrug users are engaged in more effortful cognition than non-users, despite 
the fact that there were no significant differences in performance. Future research should seek 
to clarify the reversibility of these effects, as recency of ecstasy use was a significant 
predictor in the regression analyses. The results from this research should therefore be 
considered for use in educational packages that could help inform prospective users, as well 
as individuals who have used ecstasy in the past, of the potential deleterious effect of use on 
cognitive function, prior to consideration of (re)use. 
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Table 1: Indices sleep quality, fluid intelligence and socio-demographic variables in ecstasy 
users and nonuser controls.  
 Ecstasy users 
 
     Non-users   
Males:  n, (%) 13 (65)       8 (40)  
Age (SD) 
 
21.85 (2.76)     20.89 (2.05)  
University 
degree: n (%) 
4 (20)     5 (25)  
        
Employment 
status 
       
Student; n, (%) 17 (85)     20 (100)  
Employed; n 
(%) 
2 (10)     0 (0)  
Unemployed; n 
(%) 
1 (5)     0 (0)  
        
      Mean (SD)     Mean (SD)  
        
Ravens 
Progressive 
Matrices 
(maximum 60) 
47.20 (5.64)     48.00 (6.79)  
        
ESS Score 
(maximum 24) 
 
5.00 (2.81)     5.25 (2.81)  
KSS before 4.30 (1.49)     4.75 (1.74)  
        
KSS after 5.33 (2.15)     4.06 (2.05)  
        
MEQ total 45.33 (9.31)     50.00 (9.95)  
        
UMACL anxiety 8.70 (2.56)     8.75 (2.24)  
        
UMACL 
depression  
9.05 (3.22)     8.70 (2.00)  
        
UMACL arousal 17.35 (5.38)     17.75 (3.29)  
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Table 2: Indices of drug use in ecstasy users and nonuser controls. 
                Ecstasy users Nonusers 
 Mean  sd n min max Mean  sd n min max 
Ecstasy           
Frequency*  0.37 0.51 20 0 2 - - - - - 
Use in last 30 days  2.55 3.23 20 0 10 - - - - - 
Total use  431.75 885.08 20 11 3532 - - - - - 
Weeks since 1
st
 use 206.70 155.54 20 8 572 - - - - - 
Weeks since last use 17.40 26.96 20 1 104 - - - - - 
Use in last 10 days 4.4 3.51 5 1 10 - - - - - 
           
Cannabis (joints)           
Frequency*  1.42  1.94 19 0 6 0.04 - 1 0.04 0.04 
Use in last 30 days  23.03  40.19 19 0 125 2 - 1 2 2 
Total use  1607.88  2212.54 19 1 7300 1 - 1 1 1 
Weeks since 1
st
 use 325.26 206.94 19 52 780 104 - 1 104 104 
Weeks since last use 21.26 71.55 19 1.14 312 2 - 1 2 2 
Use in last 10 days 5.82 8.74 11 1 25 - - - - - 
           
Cocaine (lines)           
Frequency*  0.26  0.39 10 0.02 1 - - - - - 
Use in last 30 days  6.42  14.80 12 0 48 - - - - - 
Total use  294.64  465.18 14 2 1576 - - - - - 
Weeks since 1
st
 use 194 142.19 14 4 520 260 - 1 260 260 
Weeks since last use 16 28.49 14 1 104 52 - - 52 52 
Use in last 10 days 3 1.41 2 2 4 - - - - - 
           
Ketamine (grams)           
Frequency*  0.24  0.32 10 0 1 - - - - - 
Use in last 30 days  0.33  0.71 9 0 2 - - - - - 
Total use  7.16  9.56 11 0.2 27.75 - - - - - 
Weeks since 1
st
 use 175.27 177.65 11 30 676 - - - - - 
Weeks since last use 27.57 31.30 11 1 104 - - - - - 
Use in last 10 days 1.22 0.69 3 0.67 2 - - - - - 
           
Alcohol (UK 
units) 
          
Use in last 10 days 19.71 14.67 19 0 50 12.98 22.60 20 0 100 
Weeks since 1
st
 use 406.63 180.75 19 242 780 307.73 144.55 19 104 572 
Weeks since last use 0.53 0.34 20 0.02 1 12.56 50.73 19 0.14 222 
Average weekly units 18.68 11.91 20 4 60 9.75 8.62 20 1 30 
 Percentages of each group reporting ever having tried a drug 
Amphetamines 10 0 
Cannabis 80 10 
Cocaine 70 5 
DMT 5 0 
GHB 10 0 
Ketamine 55 0 
LSD 5 0 
34 
 
Mushrooms 50 0 
Poppers 25 0 
Mephedrone 25 0 
* Times per week 
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Table 3: Means and SDs for Random Letter Generation (RLG) performance measures for 
ecstasy users and nonuser controls.  
     Ecstasy users           Non-users 
 Mean (SD)  Mean (SD)  
RLG 4-second rate     
Redundancy 0.087 (0.02)  0.087 (0.02)  
Repeat Sequences 11.70 (6.13)  11.10 (3.00)  
Alphabetical Sequences 5.10 (3.61)  4.30 (2.36)  
Number of Letters Produced 97.15 (11.38)  99.95 (0.22)  
     
RLG 2-second rate     
Redundancy 0.093 (0.03)  0.095 (0.02)  
Repeat Sequences 14.90 (7.35)  14.30 (3.98)  
Alphabetical Sequences 8.65 (8.22)  6.75 (3.43)  
Number of Letters Produced 95.50 (11.94)  99.20 (1.01)  
     
RLG 1-second rate     
Redundancy 0.113 (0.03)  0.11 (0.03)  
Repeat Sequences 13.95 (5.99)  15.75 (6.16)  
Alphabetical Sequences 9.95 (4.38)  10.50 (4.50)  
Number of Letters Produced 82.60 (15.09)  86.95 (12.66)  
     
 
  
36 
 
Table 4: Correlations between lifetime use of ecstasy and dependent measures.  
 Spearman’s Rho p 
1-second rate   
V11 oxy .413 <.05 
V14 oxy .323 <.05 
V2 deoxy .287 <.05 
V3 deoxy .297 <.05 
V4 deoxy .548 <.01 
V11 deoxy .369 <.05 
V13 deoxy .478 <.01 
V14 deoxy .381 <.01 
V15 deoxy .407 <.01 
V16 deoxy .307 <.05 
   
2-second rate   
V4 oxy .403 <.05 
V11 oxy .433 <.05 
V14 oxy .286 <.05 
V13 deoxy .311 <.05 
V14 deoxy .329 <.05 
V15 deoxy .376 <.01 
V16 deoxy .277 <.05 
   
4-second rate   
V3 deoxy .345 <.05 
V5 deoxy .275 <.05 
V13 deoxy .454 <.01 
V14 dexoy .396 <.01 
V15 deoxy .412 <.01 
V16 deoxy .390 <.01 
 
RLG score 2-s rate 
 
.293 
 
<.05 
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Figure 1: Anatomical locations of fNIRS channels in relation to prefrontal cortex.  
Reproduced from Kreplin & Fairclough (2013) with permission.  
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Figure 2: Mean oxy-Hb and deoxy-HB change (µmolar) from baseline during RLG at the 4s , 2-s and 1-s rates for ecstasy users (blue) and 
nonusers (red).  
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*Indicates a significant difference from non-user controls at the .05 level, and ** at the .01 level. 
 
4-second rate 2-second rate 1-second rate 
* 
